Firma Chun Cheong
Concise Prescribing Info
Healing of all grades of erosive esophagitis. Maintenance of healed erosive esophagitis & relief of heartburn. Treatment of heartburn associated w/ symptomatic non-erosive GERD.
Dosage/Direction for Use
Erosive esophagitis Childn ≥12 yr 60 mg once daily for up to 8 wk. Patients w/ moderate hepatic impairment (Child-Pugh Class B) 30 mg once daily for up to 8 wk. Maintenance of healed erosive esophagitis & relief of heartburn Adult 30 mg once daily for ≤6 mth. Patients 12-17 yr 30 mg once daily for 16 wk. Symptomatic non-erosive GERD Childn ≥12 yr 30 mg once daily for up to 4 wk.
May be taken with or without food: Swallow whole. For patients w/ swallowing difficulties, open cap & sprinkle entire contents in 1 tbsp apple sauce. Swallow immediately, do not chew. Alternatively, mix entire contents w/ water & administer using oral syringe or via a nasogastric tube (≥16 French).
Hypersensitivity. Rilpivrine-containing products.
Special Precautions
Gastric malignancy; acute interstitial nephritis; increased risk of Clostridium difficile associated diarrhea & GI infections; bone fracture; cutaneous lupus erthematosus (CLE) & SLE; vit B12 deficiency; symptomatic or asymptomatic hypomagnesemia. False positive result in diagnostic investigations for neuroendocrine tumors due to increase in serum chromogranin A levels. Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. False positive urine screening tests for tetrahydrocannabinol (THC). Concomitant use w/ methotrexate. Moderate & severe hepatic impairment. Pregnancy & lactation. Childn <12 yr.
Adverse Reactions
Diarrhea, abdominal pain, nausea, upper resp tract infection, vomiting & flatulence.
Drug Interactions
Reduced antiviral effect of antiretroviral drugs (eg, rilpivrine, atazanavir, & nelfinavir). Increased toxicity of saquinavir. Increased INR & prothrombin time w/ warfarin. May elevate & prolong serum conc of methotrexate. Potential for increased exposure of digoxin & tacrolimus. Reduced absorption of drugs dependent on gastric pH for absorption (eg, Fe salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole). Decreased exposure w/ strong CYP2C19 or CYP3A4 inducers (eg, St. John's wort, rifampin, ritonavir-containing products). Increased exposure w/ strong CYP2C19 or CYP3A4 inhibitors (eg, voriconazole).
ATC Classification
A02BC06 - dexlansoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Dexilant Cap 30 mg
Dexilant Cap 60 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in